American Society of Retina Specialists Meeting

VANCOUVER, British Columbia — At the American Society of Retina Specialists meeting, Geeta A. Lalwani, MD, discusses applying results from the RIDE and RISE trials of anti-VEGF treatment to everyday, real-world treatment of diabetic retinopathy and diabetic macular edema.

VANCOUVER, British Columbia — At the American Society of Retina Specialists annual meeting, Rishi P. Singh, MD, discusses findings from the BOULEVARD trial, which he said validated the signal of RG7716 (Genentech/Roche) as a potential molecule for the treatment of diabetic macular edema and demonstrated the agent’s “superiority to currently available therapeutics” as well as potential increased durability over time.

VANCOUVER, British Columbia — At the American Society of Retina Specialists annual meeting, Amir Kashani, MD, of the USC Roski Eye Institute, describes the use of OCT angiography to quantify retinal capillary damage that occurs in patients with radiation retinopathy.

VANCOUVER, British Columbia — Steven Yeh, MD, describes efficacy and safety findings from the PEACHTREE trial, which he presented at the American Society of Retina Specialists annual meeting. Patients who received suprachoroidal CLS-TA (Clearside Biomedical) for macular edema due to noninfectious uveitis achieved clinically meaningful visual acuity improvement at week 24 after two injections, one at baseline and one at week 12.

VANCOUVER, British Columbia — A phase 1b/2 clinical trial of AU-011, a light-activated, vision-sparing, tumor cell selective therapy for patients with choroidal melanoma, showed the treatment was safe and resulted in no vision loss for up to 12 months, according to a speaker here.

VANCOUVER, British Columbia — At the American Society of Retina Specialists meeting, Peter K. Kaiser, MD, reviews differences between Luminate (risuteganib, Allegro), which decreases oxidative stress from diabetes by blocking integrin receptors, and Avastin (bevacizumab, Genentech), which works farther downstream in the oxidative pathway, at the level of inflammation and vascular permeability.

VANCOUVER, British Columbia —Mimi Liu, MD, associates baseline characteristics and clinical features with treatment success in her presentation at the American Society of Retina Specialists meeting: “Predictors of early improvement in diabetic retinopathy severity in patients treated with ranibizumab.”

VANCOUVER, British Columbia — Early introduction of Alimera Sciences’ Iluvien implant (fluocinolone acetonide) in patients with diabetic macular edema will yield the best results in maintenance of vision and stabilization of macular edema, as well as reduction in treatment burden of adjunctive treatments, Sam E. Mansour, MD, said at the American Society of Retina Specialists meeting, where he presented data from the PALADIN and USER studies. 

VANCOUVER, British Columbia — At the American Society of Retina Specialists meeting here, Amir Kashani, MD, discusses a phase 1/2a study regarding stem cell-derived retinal pigment epithelium to improve vision loss in patients with geographic atrophy.

VANCOUVER, British Columbia — The 5-year outcomes from the DRCR.net Protocol S study support the use of either ranibizumab or panretinal photocoagulation for the treatment of proliferative diabetic retinopathy, according to a speaker here.